Early TAVR And EVOQUE Launches Will Expand Access

Published
06 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$87.12
10.2% undervalued intrinsic discount
14 Aug
US$78.26
Loading
1Y
13.6%
7D
-0.1%

Author's Valuation

US$87.1

10.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 8.71%

Shared on30 Apr 25
Fair value Decreased 0.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 0.43%

Shared on09 Apr 25
Fair value Increased 0.037%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.56%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 1.07%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.062%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 12%

AnalystConsensusTarget has increased revenue growth from 3.7% to 9.0%.